Roche Holding | ROG - Current Liabilities


Roche Holding reported CHF28.85B in Current Liabilities for its fiscal semester ending in June of 2026.





Current Liabilities Change Date
AbbVie USD 41.64B 458M Jun/2026
Alcon AG USD 3B 45M Mar/2026
Almirall EUR 323.65M 26.99M Jun/2026
Amgen USD 25.5B 547M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
Bayer EUR 33.46B 875M Mar/2026
Biogen USD 3.92B 918.2M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
Fresenius EUR 9.54B 1.15B Mar/2026
Fresenius Medical Care EUR 6.73B 484.42M Mar/2026
Genmab DKK 1.43B 686M Dec/2025
Gilead Sciences USD 11.02B 1.54B Jun/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
GRIFOLS EUR 2.24B 112M Jun/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Lakefront Biotherapeutics EUR 100.42M 52.44M Mar/2026
Lonza CHF 3.57B 421M Dec/2025
Merck EUR 9.35B 307M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Novartis USD 31.75B 374M Jun/2026
Orion EUR 454.5M 344.1M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
Philips EUR 7.42B 8M Jun/2026
Recordati EUR 1.4B 30.88M Jun/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 31.93B 1.92B Jun/2026
UCB EUR 4.4B 470M Dec/2025